Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

  • End date
    May 1, 2024
  • participants needed
  • sponsor
    Alpha Tau Medical LTD.
Updated on 20 July 2022


A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device as a neo-adjuvant therapy in men with prostate cancer


The study is planned as a prospective, open-label, one arm, single center trial, designed to assess the feasibility and safety of intratumoral DaRT seeds implantation for the treatment of local prostate cancer prior to surgery.

This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.

Prostate lesions with histopathological confirmation of adenocarcinoma will be treated using DaRT seeds in a neo-adjuvant setting.

Feasibility will be assessed by the successful delivery of DaRT seeds into the intratumoral environment. In addition, objective response rate will be assessed both by imaging and pathology.

Condition Prostate Adenocarcinoma
Treatment Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Clinical Study IdentifierNCT04543903
SponsorAlpha Tau Medical LTD.
Last Modified on20 July 2022


Yes No Not Sure

Inclusion Criteria

Pathologically confirmed, previously untreated, resectable prostate adenocarcinoma
Ability to provide tissue sample from the target or its vicinity, either from an archive or undergo another biopsy to provide a fresh sample
Medically fit for surgery
Targetable lesion must be technically amenable for complete coverage (including 3-5mm margins) by the DaRT seeds
Targetable lesion by either PSMA PET-CT according to PERCIST v1.0 OR by multiparametric MRI according RECIST v1.1
Patients must be willing to undergo imaging before and after treatment with DaRT (prior to surgery)
Lesion size ≤ 3 cm in the longest diameter
Age ≥ 18 years old
ECOG Performance Status Scale ≤ 1
Subjects' life expectancy is more than 6 months
WBC ≥ 3500/μl, granulocyte ≥ 1500/μl
Platelet count ≥ 100,000/μl
Calculated or measured creatinine clearance ≥ 60 cc/min
AST and ALT ≤ 2.5 X ULN
INR <1.4 for patients not on Warfarin
Subjects are willing and able to sign an informed consent form

Exclusion Criteria

Documented evidence of distant metastases
Prior TURP or prostate surgery
Prior pelvic radiation
Any prior pelvic malignancy or other malignancy in the last 5 years, except for cured non-melanoma skin cancer
Inability to undergo MRI (i.e. permanent implanted device incompatible with MRI)
Known hypersensitivity to any of the components of the treatment
Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months
Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints
Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after DaRT implant procedure
Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
High probability of protocol non-compliance (in opinion of investigator)
Subjects not willing to sign an informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note